EA201491277A1 - Противораковый слитый белок - Google Patents

Противораковый слитый белок

Info

Publication number
EA201491277A1
EA201491277A1 EA201491277A EA201491277A EA201491277A1 EA 201491277 A1 EA201491277 A1 EA 201491277A1 EA 201491277 A EA201491277 A EA 201491277A EA 201491277 A EA201491277 A EA 201491277A EA 201491277 A1 EA201491277 A1 EA 201491277A1
Authority
EA
Eurasian Patent Office
Prior art keywords
domain
protein
tract
sequence
amino acid
Prior art date
Application number
EA201491277A
Other languages
English (en)
Inventor
Ежи Щепан Печиколан
Себастьян Доминик Павлак
Бартломей Мацей Жерек
Петр Камиль Розга
Original Assignee
Адамед Сп.З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адамед Сп.З О.О. filed Critical Адамед Сп.З О.О.
Publication of EA201491277A1 publication Critical patent/EA201491277A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04003—Phospholipase C (3.1.4.3)

Abstract

Изобретение относится к слитому белку, включающему домен (а), который является функциональным фрагментом последовательности белка hTRAIL, начинающимся с аминокислоты в положении не ниже hTRAIL95 и заканчивающимся аминокислотой hTRAIL281, или гомологом указанногофункционального фрагмента, имеющим на по меньшей мере 70% идентичности последовательности, предпочтительно 85% идентичности, и по меньшей мере один домен (b), который является последовательностью цитолитического эффекторного пептида, образующего поры в клеточной мембране, причем последовательность домена (b) присоединена к С-концу или N-концу домена (а). Слитый белок может использоваться для лечения раковых заболеваний.
EA201491277A 2011-12-28 2012-12-22 Противораковый слитый белок EA201491277A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397595A PL223487B1 (pl) 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne
PCT/IB2012/057657 WO2013098755A2 (en) 2011-12-28 2012-12-22 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
EA201491277A1 true EA201491277A1 (ru) 2014-09-30

Family

ID=47716118

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491277A EA201491277A1 (ru) 2011-12-28 2012-12-22 Противораковый слитый белок

Country Status (28)

Country Link
US (1) US20140377216A1 (ru)
EP (1) EP2797950B1 (ru)
JP (1) JP6324905B2 (ru)
KR (1) KR20140110017A (ru)
CN (1) CN103987728B (ru)
AU (1) AU2012360086B2 (ru)
BR (1) BR112014015922A2 (ru)
CA (1) CA2859494A1 (ru)
CY (1) CY1120055T1 (ru)
DK (1) DK2797950T3 (ru)
EA (1) EA201491277A1 (ru)
ES (1) ES2655828T3 (ru)
HK (1) HK1201848A1 (ru)
HR (1) HRP20180012T1 (ru)
HU (1) HUE035794T2 (ru)
IL (1) IL232834A (ru)
LT (1) LT2797950T (ru)
MX (1) MX352796B (ru)
NO (1) NO2797950T3 (ru)
PH (1) PH12014501363A1 (ru)
PL (2) PL223487B1 (ru)
PT (1) PT2797950T (ru)
RS (1) RS56758B1 (ru)
SG (1) SG11201403282QA (ru)
SI (1) SI2797950T1 (ru)
UA (1) UA115436C2 (ru)
WO (1) WO2013098755A2 (ru)
ZA (1) ZA201405460B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
GB201406705D0 (en) 2014-04-15 2014-05-28 Univ Liverpool Fusion proteins,polynucleotides,expression vectors, and their uses
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN107216385A (zh) * 2017-05-19 2017-09-29 何向锋 肿瘤特异性重组水蛭素及其制备方法和用途
CN109400711B (zh) * 2017-05-31 2022-02-08 四川大学华西医院 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
WO2019067740A1 (en) * 2017-09-27 2019-04-04 Emory University FUSION PROTEINS COMPRISING CANCER TOXIN AND MARKER, NANOPARTICLES AND USES THEREOF
CN111909275A (zh) * 2019-05-08 2020-11-10 上海大学 延长多肽药物循环半衰期的靶向载药体系及其构建方法
CN110669146B (zh) * 2019-10-24 2023-05-23 常州大学 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN114031673B (zh) * 2021-12-22 2023-09-22 杭州长龄生物科技有限公司 一种多肽及其制备方法
CN114605517B (zh) * 2022-05-12 2022-09-27 广东海洋大学 一种具有广谱抗癌作用的多肽lxp-7及其应用
CN116063389B (zh) * 2022-08-23 2023-07-07 广州医科大学 递送核酸药物的多肽载体、***的核酸药物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0753071A1 (en) 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
NZ311982A (en) 1995-06-29 1999-08-30 Immunex Corp Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies
DE60336353D1 (de) 2003-11-03 2011-04-21 Beijing Sunbio Biotech Co Ltd Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
EP2306200A1 (en) 2005-08-16 2011-04-06 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAILl by testing for GalNac-T14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer

Also Published As

Publication number Publication date
NZ627445A (en) 2016-01-29
SI2797950T1 (en) 2018-02-28
LT2797950T (lt) 2018-02-12
PT2797950T (pt) 2018-01-24
BR112014015922A2 (pt) 2020-10-27
HK1201848A1 (en) 2015-09-11
AU2012360086B2 (en) 2016-12-22
US20140377216A1 (en) 2014-12-25
AU2012360086A1 (en) 2014-08-07
PL223487B1 (pl) 2016-10-31
JP2015504052A (ja) 2015-02-05
EP2797950A2 (en) 2014-11-05
CY1120055T1 (el) 2018-12-12
PH12014501363A1 (en) 2014-09-22
ZA201405460B (en) 2015-04-29
RS56758B1 (sr) 2018-04-30
WO2013098755A3 (en) 2013-08-29
EP2797950B1 (en) 2017-10-18
DK2797950T3 (en) 2018-01-22
PL397595A1 (pl) 2013-07-08
UA115436C2 (uk) 2017-11-10
IL232834A (en) 2017-09-28
SG11201403282QA (en) 2014-07-30
WO2013098755A2 (en) 2013-07-04
MX2014008028A (es) 2014-08-21
MX352796B (es) 2017-12-07
CA2859494A1 (en) 2013-07-04
CN103987728B (zh) 2017-05-10
IL232834A0 (en) 2014-07-31
NO2797950T3 (ru) 2018-03-17
ES2655828T3 (es) 2018-02-21
HRP20180012T1 (hr) 2018-02-09
HUE035794T2 (en) 2018-05-28
PL2797950T3 (pl) 2018-03-30
CN103987728A (zh) 2014-08-13
JP6324905B2 (ja) 2018-05-16
KR20140110017A (ko) 2014-09-16

Similar Documents

Publication Publication Date Title
EA201491277A1 (ru) Противораковый слитый белок
EA201491049A1 (ru) Противораковый слитый белок
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
EA201390820A1 (ru) Слитый белок против рака
EA201391005A1 (ru) Слитый белок против злокачественной опухоли
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
EA201691111A1 (ru) Химерные белки фактора viii и их применение
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
PE20161442A1 (es) Proteinas quimericas tipo fosfatasa alcalina
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
EA201590611A1 (ru) Новые молекулы, связывающие il-17a, и их медицинское применение
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EA201690469A1 (ru) Слитый белок
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
EA201391546A1 (ru) Противораковый слитый белок
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
AR119056A2 (es) Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada
EA201792269A1 (ru) Полипептиды, нацеленные на слияние вич
WO2015043566A8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
PH12018500468A1 (en) Fusion protein
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic